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ABSTRACT 
  
Gene Expression Profiles of Cytokines During Osteogenic Differentiation of Human 
Gingiva Derived Mesenchymal Stem Cells 
August 2015 
Reem Ahmad Almashat  
M.S., NOVA Southeastern University College of Dental Medicine  
B.D.S, King Abdulaziz University, Jeddah,Saudi Arabia  
Directed by: Dr. Umadevi Kandalam, Associate Professor, Pediatric Dentistry, NSU 
College of Dental Medicine  
 
Background: Therapeutic management of bone loss in the craniofacial region as a 
consequence of trauma, surgery or congenital malformations presents a clinical 
challenge. Mesenchymal stem cells (MSCs), due to their inherent plasticity, are potential 
candidates for cell based therapies for the repair and reconstruction of craniofacial bone 
tissue. Guided differentiation of stem cells to osteogenic precursors is marked by spatio-
temporally regulation of gene expression profiles including that of transcription factors, 
cytokines, extracellular matrix proteins, enzymes and several signaling pathways. 
Cytokines, produced by both immune and non-immune cells can influence both immuno-
modulatory responses in the host and also affect cell physiology. Understanding the 
cytokine expression profiles will be of great advantage in developing methods for 
effective bone regeneration with minimal immunological insults either on the graft or on 
the host. Objective: The objective of the present study is to investigate the gene 
expression profiles of the various cytokines of HGMSCs in normal and osteogenic 
conditions. Methodology: HGMSCs were isolated from gingival tissues by standard 
enzymatic methods. HGMSCs were guided to osteogenic precursor cells and the 
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differentiation process was monitored by measuring stage specific expression of genes 
and proteins. Mineral nodule formation of osteogenic differentiation was analyzed by 
using Alizarin red and Von Kossa Staining methods. Gene expression profiles of various 
pro- and anti-inflammatory cytokine profiles of HGMSCs were investigated using 
quantitative real time PCR at 1, 2 and 3 weeks post-induction with osteogenic medium. 
Results: The osteogenic differentiation of HGMSCs was confirmed by alkaline 
phosphate enzyme activity assay, gene and protein expression studies of osteogenic 
markers. Mineral nodule formation was observed after 4 weeks of osteogenic induction. 
The results of cytokine profile expressions revealed that there was a significant 
upregulation in the expression of TGF-β at all-time points. The gene expression of IL-10 
was more or less consistent with an overall increase of 40% over that of controls at all 
time points studied. We observed a significant decrease in the mRNA expression of IL-6 
and IL-1β with respect to their control group (P<0.05) and the expression of IL-8 was 
upregulated significantly. Conclusion: There is an overall enhancement in the expression 
of anti-inflammatory cytokines IL-10 and TGF-β during the osteogenic differentiation of 
HGMSCs that indicates a potential shift of cytokines to dampen immune responses. The 
reduction of IL-6 and IL-1β expression is an added advantage to reduce the acute phase 
and inflammatory responses, favoring HGMSCs to be cells of choice for repair and 
regeneration of craniofacial bones. A beneficial combination of the cytokines expressed 
by HGMSCs during osteogenic differentiation to reduce acute phase and long term 
immune responses will facilitate the achievement of our long term goal. 
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CHAPTER 1: INTRODUCTION  
 
1.1 Background 
 
The craniofacial region is a complex structure composed of bone, cartilage and vascular 
network. Numerous conditions such as trauma, congenital malformation and 
progressively deforming skeletal diseases may cause damage to the craniofacial region. 
In the United States, more than 15 million fractures are being treated each year 1. 
Approximately, 1,600,000 bone grafts are performed each year and 6% of those are in the 
craniofacial region 2. Craniofacial fractures are common (58.5% of total fractures) in the 
pediatric population, the majority of which are critical size defects. Reconstruction of the 
critical size bony defects using autologous bone graft requires a huge quantity of bone, 
and is associated with the donor site morbidity 3,4. Allografts, on the other hand are 
accompanied with infections and delayed bone formation 5,6. The emergence of stem cell 
based tissue engineering strategies are recognized as promising approaches to regenerate 
biological tissue substitute for critical size bony defects 7,8. Mesenchymal stem cells 
(MSCs) as a potential stem cell source for tissue engineering applications have been 
widely studied 6,9. Their high proliferative nature, self-renewal potential, ability to 
differentiate into multiple cell lineages, and their immunoprevilage nature make them a 
valuable resource for the regeneration of tissue 10.   
 
1.2 Cytokines:  
In bone tissue regeneration, MSCs display a unique capability of homing into injury or 
inflammatory sites to facilitate the repair of damaged tissue 11,12. This phenomenon is 
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mediated by several growth factors and cytokines. Cytokines are a group of small 
molecular weight proteins produced by a wide variety of cells and influence a plethora of 
other cellular behavior in an autocrine or paracrine manner 11,13. Cytokines act through 
specific receptors and regulate maturation and growth of stem cell populations. Cytokines 
can potentiate or attenuate the effects of other cytokines and influence cell signaling 
behavior. In addition, they can influence immune responses and alter host-graft 
interactions. Stem cells alter their cytokine profiles during their differentiation and in the 
host-milieu. In their effort to avoid allorecognition, many stem cells alter the local 
environment by modulating cytokine profiles 11,12. The immunosuppressive phenomenon 
of MSCs is modulated by suppressing the pro-inflammatory cytokines, such as tumor 
necrosis factor-α (TNF-α), Interleukin-6 (IL-6), Interleukin-8 (IL-8) and Interleukin-1β 
(IL-1β) and enhancing the anti-inflammatory cytokines including transforming growth 
factor- β (TGF-β) and Interleukin-10 (IL-10) 14,15.  
1.2.1 Tumor Necrosis Factor-α: 
 
TNF-α is the most potent osteoclastogenic cytokine produced during inflammation. It has 
been reported that a prolonged exposure to TNF-α leads to chronic inflammation and 
bone destruction 16. The expression of TNF-α increases immediately after bone injury, it 
then returns to base line for a few days then again is increased in later phases of bone 
formation and modeling 17. In-vivo, eradicating the signaling pathways of TNF-α has 
been shown to preclude endochondral ossification.  
 
1.2.2 Interleukin-6:  
 
Members of IL-6 family are pro-inflammatory cytokines that include IL-6, IL-11, 
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leukemia inhibitory factor, cardiostrophen and oncostatin M. IL-6 regulates the 
pleiotropic functions of tissues and cells and is crucial for bone metabolism 18,19. IL-6 as 
an osteotrophic factor, stimulates bone resorption18. IL-6 plays a major role in bone 
resorption in several physiological and pathological conditions such as bone loss due to 
estrogen deficiency, and hypercalcimia found in the blood stream of hamster ovarian 
cells that have been transfected with the IL-6 gene 18. IL-6 has an important role in 
osteogenesis of mesenchymal stem cells 20. The activity of IL-6 is employed through a 
cell surface receptor that has two components: 1) a ligand-binding IL-6 receptor (IL- 6R) 
and 2) a non-ligand-binding but signal-transducing protein gp130 (Figure 1-1). 
Cytokines that use gp130 act directly on the osteoblasts/stromal cells. However, they do 
not act on osteoclast progenitors to induce osteoclast formation. 
 
Figure 1-1. The mechanism of action of IL-6 
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1.2.3 Interleukin-1β 
 
IL-1β, a proinflammatory cytokine, plays a main role in the events of endochondral bone 
formation by human bone marrow mesenchymal stromal cells (BMMSC). It also 
contributes in remodeling of the forming hypertrophic cartilage. Low doses of IL-1β (50 
pg/mL) enhance colony-forming units- fibroblastic (CFU-f) and osteoblastic (CFU-o) in 
both number and size in the absence of further supplements 21. In osteogenic culture, IL-
1β enhances calcium deposition and BMP-2 expression by the activation of NF-κB and 
ERK signaling. IL-1β regulates both early and late events of the endochondral bone 
formation by BMMSC. TNF-α and IL-1β are considered the two master regulators of 
inflammation in fracture healing 21. 
 
1.2.4 Interleukin-8:  
 
IL-8 is a member of the alpha chemokine family of cytokines originally identified as a 
neutrophil chemo attractant. IL-8 is often associated with inflammation increased by 
oxidant stress 22,23.The expression of IL-8 and IL-1β is found to be high in the UCMSCs 
when compared to BMMSCs24. 
 
1.2.5 Interleukin-10:  
 
IL-10 is an anti-inflammatory cytokine, that inhibits T-cell proliferation and other 
effector responses 25. It works by blocking TGF-β synthesis, which acts as an endogenous 
suppressor of hematopoiesis in osteogenic cultures 26. IL-10 plays a prominent role in 
tempering immunomediated inflammation including infection, allergy, and 
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autoimmunity. MSCs derived IL-10 can facilitate suppression of T-cell proliferation and 
infiltration. It has also been shown that IL-10 attenuates the severity of graft-vs-host 
disease after allogenic stem cells transplantation 25. IL-10 has been reported as one of the 
most significant cytokines produced by the MSCs playing anti-inflammatory roles. The 
expression of IL-10 was significantly increased in cultures containing both BMMSCs and 
T cells than cultures of T cells alone 25.  
1.2.6 Transforming Growth Factor-β: 
 
TGF-β is a growth factor that promotes and maintains bone formation. In serum-free 
cultures, TGF-β was found to stimulate the formation of osteoblast-like cells and express 
bone specific markers including alkaline phosphatase (ALP) and oteocalcin 27. TGF-β 
family signaling is involved in the maintenance of embryonic stem cells identity, 
maintenance of self-renewal, proliferation and pluripotenty in both mouse and human 
embryonic stem cells 28. TGF-β1 induces Smad3-dependent nuclear accumulation of β-
catenin in MSCs, which is required for the stimulation of MSCs proliferation. Members 
of the TGF-β family have also been implicated in directing decisions regarding the fate of 
MSCs. BMPs induce differentiation of mesenchymal stem cells into cells with 
chondroblast or osteoblast phenotypes in-vitro. In most cell types, TGF-β signaling 
additionally controls the expression of a plethora of homeostatic genes whose activity 
determines cell proliferation, extracellular matrix production, paracrine factor secretion, 
cell-cell contacts, immune function, and tissue repair 29.  
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1.3 Osteogenesis 
Osteogenic differentiation is a spatio-temporally regulated event, involving stage-wise 
expression of genes that regulate a variety of growth factors and cytokines. Progression 
of stem cells to osteogenic precursor cells ensues in three distinct phases: 1) proliferation 
(Day 0- Day 4), 2) extracellular matrix maturation (Day 4 –Day14) and 3) mineralization 
(Day 14 to Day 21) 30,31. In the proliferative level (Figure 1-2), MSCs are extremely 
mitotic; they exhibit high expression of histone proteins. During the extracellular matrix 
maturation phase, MSCs condense into compact nodules. Genes associated with 
extracellular matrix proteins such as collagen type I; fibronectin and TGF-β are expressed 
during this stage. Furthermore, many non-extracellular matrix proteins including ALP, 
osteopontin and osteocalcin are upregulated. During mineralization, the MSCs will 
differentiate into osteoblasts. These cells will secrete osteoid, a collagen-proteoglycan 
matrix, that binds to calcium salts to become calcified. Most importantly, osteogenic 
differentiation is determined by two transcription factors, RUNX2 and Osterix. RUNX2, 
the master regulator of osteogenesis, influences many extracellular matrix proteins such 
as collagen type I, osteopontin, bone sialoproteins and osteocalcin.   
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Figure 1-2. Phenotypic changes during osteogenesis 
 
1.4 The aim of the study 
Many studies have reported the cytokine levels of stem cells in basic culture conditions 
32,33. However, very limited studies have focused on stem cells undergoing osteogenic 
differentiation 34,35. In this study, we propose to investigate the cytokine profiles of 
mesenchymal stem cells derived from human gingival tissue (HGMSCs) in normal and 
osteogenic conditions.  
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1.5 Human gingival mesenchymal stem cells (HGMSCs) 
Human gingival connective tissue is a reservoir of mesenchymal stem cells. HGMSCs 
can be obtained from discarded tissues in the dental clinics with minimally invasive 
procedures. HGMSCs can be easily isolated, have a high proliferative capacity, display 
stable phenotype and maintain a normal karyotype 36. The distinctive feature of HGMSCs 
is their potent immunomodulatory effects on multiple types of innate immunity cells 
especially macrophages, mast cells and dendritic cells 37.  Furthermore, 90% of which are 
originated from cranial neural crest cells (CNCC) 38. CNCC play an important role in the 
formation of tooth and alveolar bone found in the craniofacial region 38,39. 
 
1.6 Innovation: 
Our long-term goal is to develop an immunocompatible model and regenerate the bony 
tissue at the site of the defect using a novel stem cell-based system. MSCs derived from 
human gingiva are highly proliferative and efficiently differentiate into 
osteoblasts. HGMSCs, while maintaining their initial phenotype after many passages, 
they do not express HLA-dr surface molecule making them immunoprevilaged and 
potentially an excellent option for allografting.  They have been shown to be potent 
immumodulators and anti-inflammatory cells capable of improving healing in previous 
inflammatory diseases 36-38,40. Understanding the cytokine expression profiles will be of 
great advantage in developing methods for effective bone regeneration with minimal 
immunological insults either on the graft or on the host. Many studies were reported on 
the cytokine profiles of normal culture conditions in various types of stem cells 13,33-35,41,42. 
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This is the first study to investigate the gene expression profiles of cytokines of HGMSCs 
during osteogenic differentiation. The information obtained from this study will provide 
in-depth insights into cytokine-regulation of osteogenesis and will help in optimizing a 
cell-system that favors immunocompatible. 
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CHAPTER 2: MATERIALS AND METHODS  
 
2.1 Materials: 
 
Dulbecco’s Modified Eagle Medium (DMEM), Trypsin, Gene Expression Assay Mix, 
cDNA kit (Life Technology, Carlsbad, CA), Phosphate Buffered Saline (PBS), 
Penicillin/Streptomycin (Sigma; St. Louis MI) and Fetal Bovine Serum (FBS); (Atlanta 
Biologicals; Lawrenceville, GA) were used for the Study. The tissue culture flasks and 
other required lab supplies were obtained from VWR International Company (Atlanta, 
GA).   
 
2.2 Overall study design: 
The cells isolated from 6 healthy male/female donors were selected for the study. 
Isolation of HGMSCs from human gingival tissue was approved by the Institutional 
Review Board (IRB # 02071304) protocol at Nova Southeastern University. Each batch 
of cells was expanded until the cells reached confluence and subsequently were 
cryopreserved. All batches of cryopreserved HGMSCs were revived at the same time and 
cultured under standard culture conditions. Six individual experiments were conducted at 
similar experimental conditions. The cells were then induced with osteogenic medium 
and osteogenic differentiation was monitored at 1, 2, 3 and 4 weeks intervals. The cells 
cultured in complete medium (DMEM+ 10% FBS+ 1% antibiotic) served as the control 
group.  The osteogenic potential of cells cultured in growth medium with osteogenic 
supplements obtained from each batch was examined for their osteogenic potential. 
Mineralization was confirmed after 4 weeks by mineral deposition assay using Alizarin 
Red and Von Kossa. The osteogenic marker genes ALP and osteopontin were measured 
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at each time point. The gene expressions of 6 different cytokine profiles (TNF-α, IL-8, 
IL-1β, IL-6, IL-10, and TGF-β) were measured using quantitative PCR at 3 different time 
points (1, 2 and 3 weeks) (Figure 2-1, 2-2) 
 
Figure 2-1. A flow chart showing the overall study design 
 
 
 
 
HGMSCs	   Control	  (CM)	   1,2,3	  week	   RNA	  extraction	   cDNA	   Gene	  expression	  	  
TNF-­‐α	  
IL-­‐8	  
IL-­‐1β	  
IL-­‐6	  
TGF-­‐β	  
IL-­‐10	  	  
Osteogenic	  (OM)	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Figure 2-2. Study design. The figure shows HGMSCs treatment with both CM (complete 
medium) and OM (osteogenic medium) at 3 different time points (1, 2, and 3 weeks). CM 
was considered the control. 
2.3 Sample size 
Six individual experiments were conducted under similar experimental conditions. 
Cryopreserved cells obtained from 6 donors were randomly selected for the study.  There 
were 2 groups: 1) Control group: cells cultured in complete medium 2) Experimental 
group: cells cultured in osteogenic medium. The cells were harvested at 1,2 and 3 weeks 
for the gene expression studies. The sample size was as follows: 6 biological samples X 3 
time points X 6 genes X 2 culture conditions= 108 control and 108 osteogenically 
differentiated samples with a total of 216 samples (Table 1). 
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 Time points  Genes examined Gene Sequences  
 
Group I  
Control 
 
 
 week 1 
6 samples 
     CM       OM 
week 2 
6 samples  
CM       OM 
week 3 
6 samples 
CM       OM 
 
TNF-α Hs00174128_m1 
IL-8 Hs00174103_m1 
IL-1β Hs01555410_m1 
 
Group 2  
Experimental 
 
IL-6 Hs00985639_m1 
TGF-β Hs00234244_m1 
IL-10 Hs00175123_m1 
Table 1: Sample size and distribution  
2.4 Methods: 
2.4.1 Isolation of mesenchymal stem cells from gingival tissue: 
  
The gingival tissues obtained from NSU clinics were de-epithelialized and minced into 
tiny pieces (2x2 mm) and rinsed with DMEM supplemented with 10%, FBS (Life 
technology, Carlsbad, CA), 400 mmol/ml L-glutamine, 100 U/ml penicillin, 100 lg/ml 
streptomycin and 1% amphotericine 43. HGMSCs were isolated from the gingival tissue 
using standard procedures 44. Briefly, cells were digested enzymatically using 0.1% 
collagenase and 0.2% dispase for 30 minutes (Figure 2-3). The first cell suspension was 
discarded to avoid the interference of epithelial cells. The tissue samples were further 
treated with 0.1% collagenase and 0.2% dispase. Then the cell suspension was collected. 
The procedure was repeated twice and the cell suspensions were pooled. They were 
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centrifuged and the cell pellet was plated (1x2x104 cells cm2) in a tissue culture flask and 
allowed to adhere to the flask for 48 hours in a humidified incubator at 37°C and 5% CO2  
(Figure 2-4).  Each batch of cells was cultured under standard culture conditions. After 
reaching 70-80% confluency, they were cryopreserved. 
 Figure 2-3. Isolation of MSCs from human gingiva  
 
 
Figure 2-4. Cell culture incubator 
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 2.4.2 Cell culture: 
 
Cryopreserved cells were revived and resuspended in DMEM supplemented with 10% 
FBS and 1% antibiotics and seeded at 1x2x104 cells cm2 in a tissue culture flask and 
incubated at 37°C and 5% CO2. After 48 hours, non-adherent cells were removed and 
cells were fed with culture medium for every 2-3 days. Cells cultured under specific 
culture conditions were subsequently sub-cultured at 90% confluence and expanded.  
 
2.4.3 Characterization of HGMSCs by surface markers by flow-cytometry method: 
 
 Cells at the concentration of 1 x106 cells were used to measure the surface markers using 
Miltenyi Kit according to manufacturer’s instruction. The specific markers positive for 
mesenchymal stem CD 73, CD 90 and CD 105 and negative for CD 34 were identified at 
the facilities of University of Miami using a florescent activated cell sorter FACAria (BD 
Biosciences, San Jose, CA) with an adjusted florescence compensation setting. Negative 
samples were used to set up the thresholds of quadrant markers.   
 
2.4.4 In-vitro confirmation of osteogenic differentiation 
  
For the differentiation assays, the cells grown at 70-80% confluency were induced with 
osteogenic supplements including, 50 μg/ml Ascorbic Acid, 10 mM β-Glycerophosphate 
and 100 nM Dexamethasone (Dex). Osteogenic differentiation assays were performed to 
confirm the presence of mineral nodules. In order to maintain consistency, the 4th or 5th 
passage cells were used in this study.  In order to confirm osteogenic differentiation for 
every batch, cells obtained from each donor were induced with osteogenic differentiation 
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medium for four weeks. Mineralization was confirmed by both Alizarin Red and Von 
Kossa staining.  
 
2.4.5 Alizarin Red staining:  
 
 After 4 weeks of treatment, cells with or without osteogenic supplements were washed 
with PBS and fixed in 10% buffered formalin solution for 10 minutes. After rinsing with 
distilled water, the cells were incubated in 1% Alizarin Red solution for 10-15 minutes 
followed by a gentle wash with distilled water.   
 
2.4.6 Von Kossa staining: 
  
Mineral deposition was investigated after week 4 for cells treated with and without 
osteogenic media. After a designated period of time, cells were rinsed with cold PBS and 
fixed in 10% formalin for 10 minutes at room temperature. The cells were then rinsed 
twice with distilled water and incubated in 2% silver nitrate and exposed to UV light for 
30 minutes. The stain was washed and cells were exposed to bright light for 15 minutes, 
and dehydrated in 100% ethanol.  
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2.5 Gene expression studies: 
2.5.1 RNA extraction 
 
RNA was extracted from the cells using tri-reagent (Life technologies, Carlsbad, CA). 
Reverse transcription was performed to generate cDNA. About 2 ug of total RNA was 
reverse transcribed by using MMLv reverse transcriptase using cDNA synthesis kit as per 
manufacturer’s instructions. The total RNA was used for cDNA synthesis by reverse 
transcriptase with a (Figure 2-5).  
 
Figure 2-5. Experimental procedure showing gene expression study  
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2.5.2 Quantitative PCR and cDNA preparation: 
 
The reverse transcriptase products were amplified with primers (Table 1) specific for 
TNF-α, IL-1β, IL-6, IL-8, IL-10, TGF-β and β-actin a housekeeping gene, using a gene 
expression assay kit (Life Technology, Carlsbad, CA). Real-time PCR was performed 
and monitored by using a StepOne Plus Real-Time PCR System (Life Technologies, 
Charlsbad, CA). cDNA was analyzed by commercially available primers and probes from 
Life Technologies (Carlsbad, CA) following the manufacturer’s instructions. 
 
2.6 Statistical analysis:  
To evaluate differences between or among groups, paired t-test and analysis of variance 
(ANOVA) were performed. A P-value < 0.05 was selected for significance. For all the 
data analysis, GraphPad Prism 5 software was used.  
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CHAPTER 3: RESULTS 
 
3.1 Cellular morphology: 
The cells with passages 4 and 5 were used for all the experiments. Cell suspension was 
seeded at a density of 1x106 and cultured under standard culture conditions. The cells 
were tightly adhered after 36 hours after seeding and were widely spread showing 
fibroblast morphology.  The cells reached 70-80% confluency after one week (Figure 3-
1). 
Cell Culture 
 
       
a)                                                                b) 
	  	  	  	  	  	  	    
c)                                                               d) 
 
Figure 3-1. A microscopic view showing: a) HGMSCs plated in T75 flask at day 0. b) 
HGMSCs at day 1. c) Cells at sub-confluence. d) Cells stained with florescent showing 
viable cells (green cells). Red color indicates dead cells 
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3.2 Cell surface markers: 
The flow cytometry data revealed that the cells were positive for mesenchymal stem cells 
markers CD73, CD90, CD105. They were negative for haemopoietic stem cells markers 
CD34. All batches of cells were examined for their surface markers (Figure 3-2). 
 
 
 
 
Figure 3-2. Flow cytometry showing HGMSCs surface markers 
 
 
3.3 In-vitro assays to confirm osteogenic differentiation: 
The cells obtained from each donor were examined for their osteogenic potential. Various 
assays were conducted including ALP activity, osteogenic marker gene expression and 
mineralization to determine osteogenic potential.  
CD	  105 CD	  90 
CD	  73 CD	  14-­‐/CD20-­‐
/CD34-­‐/CD45-­‐ 
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3.3.1 ALP activity: 
 
The results of ALP activity indicated that there was a gradual increase in ALP activity at 
7 and 14 days post induction. Over 48% increase at the 7th day followed by 71% increase 
at the 14th day was observed (Figure 3-3).  
 
 
 
Figure 3-3. ALP enzyme activity, an early marker for osteogenic differentiation is 
increased at 1 week and 2 weeks 
 
 
 
 
 
 
 
3.3.2 Osteogenic marker genes: 
 
 In order to confirm the differentiation, various osteogenic marker genes were 
investigated. The cells obtained from all batches showed expression of osteoblast specific 
genes such as ALP, Collagen type I and osteopontin.  The results of RT-PCR 
0	  20	  
40	  60	  
80	  100	  
120	  140	  
160	  180	  
200	  
1	  week	   2	  weeks	  
ALP	  Enzyme	  Activity	  
Control	  OM	  
*	   *	  
	   22	  
demonstrated that there was a significant upregulation of mRNA expression in all genes 
(Figure 3-4). 
 
 
 
Figure 3-4. Gene expression of osteogenic markers 
 
 
3.4 In-vitro mineralization experiments: 
Mineralization is the hallmark for osteogenically differentiated cells.  The cells induced 
with or without osteogenic supplements were monitored at weekly intervals to examine 
mineral nodule formation. Our results revealed that after 4 weeks of osteogenic induction, 
the cells showed mineral nodules (Figure 3-5). 
 
ALP 
Type	  I	  Collagen 
1	  week 2	  weeks 
B	  actin	   Endogenous	  control 
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Figure 3-5. In-vitro mineralization: HGMSCs 4 weeks mineralization with Alizarin Red 
(A&B) and Von Kossa (C&D). A&C shows cells treated in CM, B&D shows cells 
treated in OM 
 
 
3.5 mRNA expression profiles of cytokines: 
To examine the changes in cytokine expression in undifferentiated and osteogenically 
differentiating cells, the cells cultured with or without osteogenic supplements were 
harvested at 7, 14 and 21 days’ time intervals. A total of 6 cytokines were selected for the 
study. The mRNA expression was measured using quantitative PCR method at the 
designated time points. The results obtained from all six biological samples were 
analyzed in this study. The quantitative PCR experiments were conducted using 3 
replicas from each sample. The average value of the experimental group (cells induced 
with osteogenic medium) was compared with the average of the control (cells devoid of 
osteogenic supplements). The relative gene expression was measured by using 2 δδ Ct 
method.  
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Gene expression profiles of the cytokines in this study revealed interesting findings. The 
overall results demonstrated that the gene expression levels of cytokines were altered 
during the differentiation of the MSCs. In our study, we measured the gene expressions 
of TGF-β, IL-10 (anti-inflammatory cytokines), IL-6, IL-8, TNF-α and IL-1β (pro-
inflammatory cytokines). The results of our study demonstrated that the cytokines 
including TGF-β, IL-6, IL-8, IL-10 and IL-1β were expressed in undifferentiated and 
differentiated cells. However, it is interesting to note that TNF-α was expressed in 
undifferentiated cells obtained from two donors, but none of the differentiated cells 
expressed TNF-α at any time point. Our results revealed that the relative gene expression 
of IL-6 and IL-1β was significantly down regulated in Dex induced cells when compared 
to control (cells cultured without osteogenic supplements) in HGMSCs. Furthermore, 
there was a time dependent down regulation observed in the cells treated with osteogenic 
induction medium.  
Our results revealed that there was an upregulation in the expression of TGF-β. While 
there was an 82% increase in the expression at day 7, a slight decrease was observed at 
day 14 and a gradual increase at day 21. There was an increase in the expression of IL-10 
with a range from 39% to 41% at all-time points. There was significant decrease 
observed in the expression of IL-6 and IL-1β compared to the control group at all time 
points. It is interesting to note that the IL-6 expression was down regulated by 27% at 
week 2 when compared to 1 week cell cultures with a gradual increase at 3 week time 
point. The levels of IL-8 were significantly increased at 1 and 2 week time points 
(Figures 3-6 à 3-10) 
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 IL-10 
 
 
 
 
 
Figure 3-6. HGMSCs were induced with osteogenic medium (OM) for 1, 2 and 3 weeks and compared to 
control (cells grown in complete medium without osteogenic supplements). The figure shows the relative 
gene expression of IL-10. a) Cells cultured in complete medium with or without osteogenic supplements 
for 7 days. b) Cells cultured in complete medium with or without osteogenic supplements for 14 days. c) 
Cells cultured in complete medium with or without osteogenic supplements for 21 days. 
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TGF-β 
 
 
 
 
 
Figure 3-7. HGMSCs were induced with osteogenic medium (OM) for 1, 2 and 3 weeks and compared to 
control (cells grown in complete medium without osteogenic supplements). The figure shows the relative 
gene expression of TGF-β. a) Cells cultured in complete medium with or without osteogenic supplements 
for 7 days. b) Cells cultured in complete medium with or without osteogenic supplements for 14 days. c) 
Cells cultured in complete medium with or without osteogenic supplements for 21 days. 
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 IL-1β 
 
 
 
 
 
Figure 3-8. HGMSCs were induced with osteogenic medium (OM) for 1, 2 and 3 weeks and compared to 
control (cells grown in complete medium without osteogenic supplements). The figure shows the relative 
gene expression of IL-1β. a) Cells cultured in complete medium with or without osteogenic supplements 
for 7 days. b) Cells cultured in complete medium with or without osteogenic supplements for 14 days. c) 
Cells cultured in complete medium with or without osteogenic supplements for 21 days. 
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 IL-6 
 
 
 
 
 
Figure 3-9. HGMSCs were induced with osteogenic medium (OM) for 1, 2 and 3 weeks and compared to 
control (cells grown in complete medium without osteogenic supplements). The figure shows the relative 
gene expression of IL-6. a) Cells cultured in complete medium with or without osteogenic supplements for 
7 days. b) Cells cultured in complete medium with or without osteogenic supplements for 14 days. c) Cells 
cultured in complete medium with or without osteogenic supplements for 21 days. 
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 IL-8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-10. HGMSCs were induced with osteogenic medium (OM) for 1 and 2 weeks and compared to 
control (cells grown in complete medium without osteogenic supplements). The figure shows the relative 
gene expression of IL-8. a) Cells cultured in complete medium with or without osteogenic supplements for 
7 days. b) Cells cultured in complete medium with or without osteogenic supplements for 14 days. 
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CHAPTER 4: DISCUSSION  
 
 
MSCs, due to their inherent plasticity, are potential candidates for cell based therapies for 
the repair and reconstruction of the craniofacial bone tissue. According to minimal 
criteria of the International Society of Cellular Therapy (ISCT), in order to be considered 
as MSCs, they need to follow three important criteria. 1) Cells need to adhere to plastic 
surface and 2) they should express specific panel of surface markers and 3) differentiate 
into osteogenic, chondrogenic and adipogenic lineages under specific culture conditions. 
In parallel to their role as undifferentiated cell reserves, MSCs have immunomodulatory 
functions which are exerted by cytokines. Cytokines or growth factors are decision 
makers of cell fates toward survival versus death and interaction versus protection.  In 
addition to their immuno-modulatory responses they regulate stem cell differentiation. 
The present study was focused on the elucidation of gene expression profiles of various 
cytokines and their role during osteogenic differentiation of HGMSCs.    
 
In this study, we demonstrated that HGMSCs were positive to mesenchymal stem cell 
surface markers. The results of the study confirmed that HGMSCs can potentially 
differentiate to osteogenic lineage. The overall results demonstrated that the expression of 
cytokine levels altered during osteogenic differentiation. (Table 2) summarizes the in-
vitro studies of the cytokines expression.  
 
 In our study, while undifferentiated and osteognically differentiating cells expressed 
TGF-β, the increase in the expression of TGF-β in osteogenically differentiated cells 
ranged from 50-80% at the designated time points. TGF-β is one of the most predominate 
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immunomodulatory cytokines produced and constitutively secreted by MSCs. TGF-β is 
involved in a cell-contact dependent inhibition of T-cell proliferation by MSCs 29.  
IL-10 is the most commonly discussed cytokine in relation to its immunomodulatory 
effects on MSCs. However, according to previous reports, the secretion of IL-10 is quite 
contradictory. While few researchers reported the secretion of IL-10 by MSCs, others 
reported that MSCs secrete IL-10 only under specific conditions 11. IL-10 inhibits the 
production of Th1 and proinflammatory cytokine TNF-α. MSCs produced high levels of 
IL-10 when they were co-cultured with the lymphocytes. In our study, the IL-10 levels 
were upregulated around 40% in osteogenically differentiated cells compared to 
undifferentiated cells at all-time points observed. Vlasselaer et al demonstrated an 
interesting finding that the cells induced with IL-10 inhibited the osteogenic activity in 
mouse BMMSC 26. However, the IL-10 did not affect the ongoing synthesis of ALP and 
collagen during the first 9 days of the culture; nevertheless it maximally suppressed these 
proteins at day 15 –day 18 when the cells were induced with IL-10 from the day 1 
culture.    
 
TNF-α and IL-1β play an important role in bone metabolism and regulate the function of 
osteoblasts and osteoclasts. In our study, TNF-α gene expression was randomly observed 
in both undifferentiated and differentiated conditions. The expression of TNF-α was 
observed only in the undifferentiated cells obtained from two donors of the cells obtained 
from 6 donors. Osteogenically differentiating cells did not express TNF-α. The limited 
number of donors might be a limitation in the study, and it could be cell type dependent. 
In Kim et al studies, the protein expression of TNF-α was minimal in both 
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undifferentiated and differentiated cells of BMMSCs 45. Furthermore, Sumansinghe et al 
reported that mechanical strain has minimal effect on the expression of TNF-α 46. Taken 
together, during osteogenic conditions, mechanical stimulus might not influence the 
levels of TNF-α. 
 
Our data demonstrated that IL-1β was expressed in undifferentiated and differentiated 
cells. There was a gradual down regulation in the expression level (p=<0.05) in the 
osteogenically differentiating cells compared to control at all-time points tested.  Kim et 
al reported the IL-1β expression was insignificant in BMMSCs cultured in basal medium 
as well as differentiating medium 45.  In mechanically strained BMMSCs significantly 
low levels of IL-1β were observed at later point of time. They predicted that IL-1β might 
have expressed at the earlier time points in their study 46.  
 
In our study, the expression of IL-8 increased in time dependent manner with maximal 
expression at week 2. Our results were in agreement with the study of Sumansinghe et al 
46. This group of researchers found an enhanced expression of IL-8 in the continuous 
presence of 100nM Dex. Furthermore, they showed that the mechanical strain enhanced 
the IL-8 expression significantly during the days 1-3 and 6-9 days relative to unstrained 
controls. While Dex dependent down regulation of IL-8 has been observed by Chaudhary 
et al in BMMSCs 47, Kim et al 45 studies demonstrated a significant increase in IL-8 
expression in the same cells model when the cells were induced with Dex for 14 days. 
Taken together, it was predicted that the expression levels depend on the duration of Dex 
induction in the culture medium. It is interesting to note that our results demonstrated that 
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the IL-8 expression in undifferentiated cells was insignificant at week 3. On the other 
hand osteogenically differentiated cells exhibited high levels of IL-8 expression. From 
the above studies, we have predicted that Dex might be influencing the IL-8 expression.  
 
Our results revealed that the cells undergoing osteogenic differentiation have 
significantly down regulated the expression of IL-6 in HGMSCs.  It was also observed 
that the IL-6 expression was down regulated in time dependent manner. Cells incubated 
in the osteogenic supplements for two weeks inhibited IL-6 expression by 50 to 25% than 
cells incubated in normal culture conditions. Our results were in agreement with the 
results observed in bone marrow stem cells. Studies have shown that the expression of 
IL-6 was inhibited by bone marrow derived MSCs when treated with Dex in the culture 
medium 8. These findings were also supported by another study reporting the reduction in 
the expression of IL-6 when MSCs were subjected to osteogenic differentiation 42,45.  In 
another study, IL-6 expression was observed to be down regulated after the first day of 
Dex in cell culture 46.  The same study indicated that IL-6 mechanical stimuli decrease 
the inhibition of IL-6 expression by dexamethasone. Irradiation of MSCs by cyclic strain 
enhances the release of IL-6 even with the presence of dexamethasone in cell culture 46. It 
is interesting to note that Li et al have demonstrated that when BMMSCs and peripheral 
blood leucocytes undergo differentiation, there was a decrease in IL-6 level 48. It suggests 
that IL-6 down regulation was differentiation dependent but not cell phenotype 
dependent. Their study showed a significant decrease in IL-6 mRNA expression in 
vascular endothelial growth factor (VEGF) induced endothelial cells compared with 
undifferentiated MSCs. The in vivo study of Li et al on cardiovascular tissue engineering 
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demonstrated that when allogenic stem cells were implanted in rat infraction model they 
improved cardiac function, but after the cells were myogenically differentiated, they lost 
the immunoprevilage property and there was cellular rejection 48. All these studies 
collectively state that IL-6 might have immunosuppressive properties and modulation of 
IL-6 may improve the immunoprevilage property of MSCs. 
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Author Year Cell type Culture condition Cytokines 
Kim et al 2005 Human 
Bone 
marrow 
MSC 
Complete medium 
 
 
 
• IL-6, IL-8, were expressed 
• IL-1β was not expressed 
Osteogenic medium  • IL-6 decreased expression 
• IL-8 was expressed 
• IL-1β was not expressed 
Samanasunghe 
et al 
2008 Human 
Bone 
marrow 
MSC 
Complete medium 
 
 
• TNF-α anf IL-1β had very 
low expression  
• IL-6 increased 
• IL-8 less expression 
Complete medium+ 
cyclic strain  
• TNF-α and IL-1β had very 
low expression  
• IL-6 decreased 
• IL-8 increased expression or 
the first 3 days 
Osteogenic medium  • TNF-α and IL-1β had very 
low expression  
• IL-8 greatest expression 
 
Osteogenic 
medium+ cyclic 
strain  
• TNF-α and IL-1β had very 
low expression  
• IL-6 increased  
• IL-8 decreased expression 
with 10% strain 
Malaval et al 1998 Rat 
calvaria 
cells  
Complete medium 
without Dex 
 
• IL-6 expression observed  
Complete medium 
with Dex 
• IL-6 expression decreased 
Hwang et al 2009 Human 
bone 
marrow 
 
Cord blood 
 
Amnion 
and 
decidua of 
placenta 
Complete medium 
 
 
• IL-6 and IL_8 were 
expressed by all cell types 
• IL-6 was lower in cord 
blood  
Park et al 2009 Human 
Bone 
marrow 
MSC 
Complete medium 
 
• IL-6 high expression 
• IL-8 moderate expression  
• TGF-β detected with no 
measurable value  
Table 2: In-vitro studies of various authors on cytokines expression studies  
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CONCLUSION 
 
 
There is an overall enhancement in the expression of anti-inflammatory cytokines IL-10 
and TGF-β during the osteogenic differentiation of HGMSCs indicating a potential shift 
of cytokines to dampen immune responses. The reduction of IL-6 and IL-1β expression is 
an added advantage to reduce acute-phase and inflammatory responses, favoring 
HGMSCs to be the cells of choice for repair and regeneration of craniofacial bones. A 
beneficial combination of the cytokines expressed by HGMSCs during osteogenic 
differentiation to reduce acute phase and long term immune responses will facilitate the 
achievement of our long term goal. 
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 APPENDICES 
 
Gene Expression of IL-10 
 
1	  week	   	  2	  weeks	   3	  weeks	  
CM	   OM	   CM	   OM	   CM	   OM	  
1	   1.90	   1	   1.01	   1	   1.288	  
1	   1.26	   1	   1.41	   1	   1.66	  
1	   1.26	   1	   1.64	   1	   1.37	  
1	   1.26	   1	   1.52	   1	   1.7	  
1	   1.15	   1	   1.58	   1	   1.22	  
1	   1.54	   1	   1.22	   1	   1.13	  
1	   1.51	  
	   	   	   	  
	   	   	   	   	   	  Mean	   1.41	   Mean	   1.396667	   Mean	   1.394667	  
Sd	   0.26	   Stdev	   0.240389	   StDEV	   0.256184	  
	   	   	   	   	   	  P	  value	   0.0056	   P	   0.0099	   P=	   0.0103	  
	  
**	   Stdev	   **	  
	  
*	  
 
 
 
 
 
Gene Expression of IL-6 
 
1	  week	   2	  weeks	   3	  weeks	  
	   	   	   	   	   	  1	   0.77	   1	   0.24	   1	   0.11	  
1	   0.13	   1	   0.05	   1	   0.53	  
1	   0.11	   1	   0.12	   1	   0.08	  
1	   0.74	   1	   0.09	   1	   0.52	  
1	   0.12	   1	   0.25	   1	   0.93	  
1	   0.77	   1	   0.28	   1	   0.71	  
Mean	   0.44	  
	   	   	   	  SD	   0.31	   Mean	   0.17	   Mean	   0.48	  
	   	  
SD	   0.10	   Stdev	   0.34	  
P=	   0.01	  
	   	   	   	  
	  
*	   P	   <	  0.0001	   P	   0.01 
	   	   	  
***	  
	  
*	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Gene Expression of IL-1 
 
1	  Week	  Data	   2	  Weeks	  ‘Data	   3	  weeks’	  Data	  	  
CM	   OM	   CM	   OM	   CM	   OM	  
1	   0.86	   1	   0.05	   1	   0.601	  
1	   0.08	   1	   0.46	   1	   0.0589	  
1	   0.59	   1	   0.95	   1	   0.456	  
1	   0.14	   1	   0.12	   1	   0.285	  
1	   0.85	   1	   0.18	   1	   0.307	  
1	   0.04	   1	   0.67	   1	   0.659	  
	   	  
1	   0.36	  
	   	  Mean	   0.43	  
	   	  
Mean	   0.39	  
SD	   0.39	   Mean	  	   0.40	   STDEV	   0.22	  
P	  
Value	   0.0421	   SD	   0.33	  
	   	  
	  
*	  
	   	  
P	  value	   0.009	  
	   	   	   	   	  
**	  
	   	  
P	  	  Value	   0.0027	  
	   	  
	   	  
Significance	   **	  
	   	   
 
 
 
 
 
Gene Expression of IL-8  
 
1	  WEEK	   2	  WEEKS	  
CM	   OM	   CM	   OM	  
1	   7.68	   1	   6.25	  
1	   4.60	   1	   12.44	  
1	   4.07	   1	   9.24	  
1	   9.38	   1	   3.50	  
1	   7.56	   1	   4.49	  
Mean	   6.66	   1	   2.55	  
SD	   2.01	   Mean	   6.41	  
P	  value	   0.02 SD	   3.78	  
	  
* P	   0.02 
	   	   	  
*	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Gene Expression of TGF-β  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 week	   2 weeks	   3 weeks	  
CM OM CM OM CM	   OM 
	   	   	   	  
1	   1.563	  
1	   1.34	   1	   1.62	   1	   1.39	  
1	   2.18	   1	   1.30	   1	   2.7	  
1	   1.23	   1	   1.39	   1	   1.7	  
1	   2.03	   1	   2.09	   1	   1.94	  
1	   1.8	   1	   1.29	  
	   	  1	   2.34	  
	   	   	   	  
	   	   	   	   	   	  Mean	   1.82	   Mean	   1.5382	   Mean	   1.8586	  
SD	   0.45	   SD	   0.34	  
	  
0.5115	  
P=	   0.0068	   P= 0.0233	   P=	   0.0199	  
	  
**	  
	  
*	  
	  
*	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